Nanovaccine: A Hope to Triumph the Battle Against Novel Coronavirus Disease 2019 (COVID-19).

IF 2 4区材料科学 Q3 MATERIALS SCIENCE, MULTIDISCIPLINARY

Recent Patents on Nanotechnology Pub Date : 2023-01-01 DOI:10.2174/1872210515666210720130736

Anurag Singh, Anand Maurya, Gaurav Mishra, Rajendra Awasthi, Kamal Dua, Giriraj Kulkarni

{"title":"Nanovaccine: A Hope to Triumph the Battle Against Novel Coronavirus Disease 2019 (COVID-19).","authors":"Anurag Singh, Anand Maurya, Gaurav Mishra, Rajendra Awasthi, Kamal Dua, Giriraj Kulkarni","doi":"10.2174/1872210515666210720130736","DOIUrl":null,"url":null,"abstract":"Background: The novel coronavirus 2019 (COVID-19) infection has caused the global emergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmed global COVID-19 cases and deaths reached 158551526 and 3296855, respectively.Methods: Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2. Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infection can be halted only when an effective vaccine will be developed.Results: Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNA vaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/subunit protein vaccines, peptide vaccines, virus-like particles, etc. Inactivated virus vaccines and mRNA, and adenovirus-based vaccines have moved fast into patent clinical trials.Conclusion: Vaccines containing spike protein of SARS-CoV as subunit could effectively prevent binding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a major target for subunit vaccine preparation.","PeriodicalId":49324,"journal":{"name":"Recent Patents on Nanotechnology","volume":"17 1","pages":"15-17"},"PeriodicalIF":2.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent Patents on Nanotechnology","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.2174/1872210515666210720130736","RegionNum":4,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The novel coronavirus 2019 (COVID-19) infection has caused the global emergence of coronavirus in humans during the last 12 months. Till May 11, 2021, the confirmed global COVID-19 cases and deaths reached 158551526 and 3296855, respectively.

Methods: Goblet cells and ciliated cells in the nose act as the initial infection site of SARS-CoV-2. Thus, mucus immunity is important to protect from infection. The outburst of SARS-CoV-2 infection can be halted only when an effective vaccine will be developed.

Results: Globally, over 100 different vaccines are under investigation, including DNA vaccines, RNA vaccines, inactivated virus vaccines, adenovirus-based vaccines, recombinant/subunit protein vaccines, peptide vaccines, virus-like particles, etc. Inactivated virus vaccines and mRNA, and adenovirus-based vaccines have moved fast into patent clinical trials.

Conclusion: Vaccines containing spike protein of SARS-CoV as subunit could effectively prevent binding of coronavirus to the host cell and membrane fusion. Thus, spike protein can be used as a major target for subunit vaccine preparation.

查看原文本刊更多论文

纳米疫苗:战胜2019年新型冠状病毒病(COVID-19)的希望

背景:在过去的12个月中，新型冠状病毒2019 (COVID-19)感染导致全球出现了人类感染冠状病毒。截至2021年5月11日，全球新冠肺炎确诊病例158551526例，死亡病例3296855例。方法:鼻部杯状细胞和纤毛细胞作为SARS-CoV-2的初始感染部位。因此，粘液免疫对防止感染很重要。只有开发出有效的疫苗，才能遏制SARS-CoV-2感染的爆发。结果:全球有100多种不同的疫苗正在研究中，包括DNA疫苗、RNA疫苗、灭活病毒疫苗、基于腺病毒的疫苗、重组/亚单位蛋白疫苗、肽疫苗、病毒样颗粒等。灭活病毒疫苗和mRNA以及基于腺病毒的疫苗已迅速进入专利临床试验阶段。结论:以SARS-CoV刺突蛋白为亚基的疫苗可有效阻止冠状病毒与宿主细胞的结合和膜融合。因此，刺突蛋白可以作为亚单位疫苗制备的主要靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Recent Patents on Nanotechnology NANOSCIENCE & NANOTECHNOLOGY-MATERIALS SCIENCE, MULTIDISCIPLINARY

CiteScore

4.70

自引率

10.00%

发文量

审稿时长

3 months

期刊介绍： Recent Patents on Nanotechnology publishes full-length/mini reviews and research articles that reflect or deal with studies in relation to a patent, application of reported patents in a study, discussion of comparison of results regarding application of a given patent, etc., and also guest edited thematic issues on recent patents in the field of nanotechnology. A selection of important and recent patents on nanotechnology is also included in the journal. The journal is essential reading for all researchers involved in nanotechnology.